A5051616970- Cancer Diagnosis and Treatment
- Bone health and treatments
- RNA modifications and cancer
- Signaling Pathways in Disease
- Cancer, Hypoxia, and Metabolism
- Management of metastatic bone disease
Jiangsu Hengrui Medicine (China)
2025
Wuhan University of Science and Technology
2024
The Central Hospital of Xiao gan
2024
Xian Central Hospital
2020
ABSTRACT Trastuzumab and pertuzumab combined with chemotherapy represent the standard therapy for first‐line treatment of HER2‐positive metastatic breast cancer (BC). Due to challenges related availability cost in China, it is necessary explore treatments involving tyrosine kinase inhibitors (TKIs). In this multicenter, single‐arm, open‐label phase II trial, patients BC were enrolled from seven hospitals China. Patients received oral pyrotinib 400 mg once daily intravenous nab‐paclitaxel 125...
Background: Triple-negative breast cancer (TNBC) is a subtype of with poor prognosis, and the outcomes common therapy were not favorable. Methods: The samples 84 patients TNBC 40 fibroadenoma collected in pathology department specimen library our hospital. prognosis was obtained through outpatient follow-up information, telephone WeChat contacts, medical records. mRNA expression analyzed using bioinformation quantitative real-time polymerase chain reaction (qPCR). protein determined by...
Abstract Purpose It was controversial to operate on the primary site of breast cancer with simple bone metastasis，we found that surgery could improve survival in patients metastases via a SEER database retrospective analysis. Method Totolly 2917 cases metastasis, first diagnosed between 2010 and 2015 National Cancer Institute surveillance, Epidemiology, Results Database (SEER).We assessed effect different surgical procedures prognosis by correlation statistics. Compared non-surgical group ,...